Cor Vasa 2020, 62(1):6-16 | DOI: 10.33678/cor.2020.010

(The prevalence of major cardiovascular risk factors in the Czech population in 2015-2018. The Czech post-MONICA study)

Renata Cífkováa,b, Jan Bruthansa, Peter Wohlfahrta, Alena Krajčoviechováa, Pavel Šulca, Lenka Eremiášováb, Jan Pudilb, Aleš Linhartb, Jiří Widimský Jr.c, Jan Filipovskýd, Otto Mayer Jr.d, Věra Lánskáe, Rudolf Polednef, Petr Stávekf
a Centrum kardiovaskulární prevence, 1. lékařská fakulta Univerzity Karlovy a Thomayerova nemocnice s poliklinikou, Praha
b II. interní klinika kardiologie a angiologie, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze
c III. interní klinika, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze
d II. interní klinika, Lékařská fakulta v Plzni, Univerzita Karlova a Fakultní nemocnice Plzeň
e Oddělení lékařské statistiky, Institut klinické a experimentální medicíny, Praha
f Laboratoř pro výzkum aterosklerózy, Institut klinické a experimentální medicíny, Praha

Cardiovascular disease (CVD) is the main cause of death in the Czech Republic. The decline in CVD mortality observed in our country since 1985 may be due to a decrease in its incidence or case fatality. Case fatality is mostly related to the standard of health care whereas the incidence of CVD is associated with the risk profile of the population. The aim of this study was to determine the prevalence of major CVD risk factors in a representative Czech population sample.

Methods: A 1% population sample aged 25-64 years was randomly selected from nine districts of the Czech Republic. The examination consisted of completing a standard questionnaire, obtaining major anthropometric data, repeated blood pressure measurements, and blood sampling.

Results: A total of 2621 individuals (1250 males, mean age 48.3 ± 10.9 years, and 1371 females, mean age 47.7 ± 11.00 years; p < 0,001) were screened in 2015-2018 (response rate, 44.8%). Mean BMI in our population was 29.1 ± 4.8 kg/m2 in males and 27.5 ± 6.1 kg/m2 in females (p < 0.001). Obesity was found in 37.3% of males and 28.2% of females. Among the males, 24.8% reported to be regular smokers whereas smoking was found in 21.6% females (p < 0.001). There was a high prevalence of hypertension (48.6% of males and 32.4% of females; p < 0.001); 74.3% of hypertensives were aware of their disease, 61.5% were drug treated, however, only 33.9 % were controlled (blood pressure < 140/90 mmHg). The mean total cholesterol in our population was almost identical in males and females (5.26 ± 1.03 mmol/L and 5.28 ± 1.00 mmol/L, respectively). Lipid-lowering drugs were used by 13.9% of males and 10.2% of females (p < 0.001). Diabetes was found in 8.2% of males and 4.6% of females (p < 0.001). The prevalence of all major risk factors increased significantly with age in both sexes (p for trend < 0.001).

Conclusion: A high prevalence of major cardiovascular risk factors was found in a representative Czech population sample, which is the cause of continuing high cardiovascular mortality in the Czech Republic.

Keywords: Blood pressure, BMI, Cardiovascular disease, Hypertension, Population random sample, Smoking, Total cholesterol

Received: February 4, 2020; Accepted: February 4, 2020; Published: February 28, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Cífková R, Bruthans J, Wohlfahrt P, Krajčoviechová A, Šulc P, Eremiášová L, et al.. (The prevalence of major cardiovascular risk factors in the Czech population in 2015-2018. The Czech post-MONICA study). Cor Vasa. 2020;62(1):6-16. doi: 10.33678/cor.2020.010.
Download citation

References

  1. Zemřelí 2017, ÚZIS, ČR, 2018.
  2. Wilkins E, Wilson L, Wickramasinghe K, et al. European Cardiovascular Disease Statistics 2017. European Heart Network, Brussels, 2017.
  3. WHO MONICA Project Principal Investigators: The World Health Organization MONICA project (Monitoring trends and determinants in cardiovascular disease): A major international collaboration. J Clin Epidemiol 1988;41:105-114. Go to original source... Go to PubMed...
  4. Tunstall-Pedoe H, Kuulasma K, Mähönen M, et al., for the WHO MONICA (Monitoring trends and determinants in cardiovascular disease) Project. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet 1999;353:1547-1557. Go to original source... Go to PubMed...
  5. Yusuf S, Hawken S, Ôunpuu S, et al. and INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study. Lancet 2004;364:937-952. Go to original source... Go to PubMed...
  6. Bruthans J, Cífková R, Lánská V, et al. Explaining the decline in coronary heart disease mortality in the Czech Republic between 1985 and 2007. Eur J Prev Cardiol 2014;21:829-839. Go to original source... Go to PubMed...
  7. Food consumption data released by the Czech Statistical Office at: https://www.czso.cz: table 03.02: Food consumption and non-alcoholic beverages in 1989-2018. https://www.czso.cz/documents/10180/91917746/32018119_0302.pdf/356ce8ab-1ede-4e5a-98c4-090ab2c8a542?version=1.1.
  8. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14(Supp 2):S1-S88. Go to original source... Go to PubMed...
  9. American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes - 2019. Diabetes Care 2019;42(Suppl. 1):S13-S28. Go to original source... Go to PubMed...
  10. Cífková R, Bruthans J, Adámková V, et al. Prevalence základních kardiovaskulárních rizikových faktorů v české populaci v letech 2006-2009. Studie Czech post-MONICA. Cor Vasa 2011;53:220-229. Go to original source...
  11. Cífková R, Skodová Z, Bruthans J, et al. Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. Atherosclerosis 2010;211:676-681. Go to original source... Go to PubMed...
  12. Leenen FH, Dumais J, McInnis NH, et al. Results of the Ontario survey on the prevalence and control of hypertension. CMAJ 2008;178:1441-1449. Go to original source... Go to PubMed...
  13. Vollenweider P. Setting up the CoLaus study. BMC Proceedings 2013;7(suppl. 5):O6. Go to original source...
  14. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, et al.; for the WHO MONICA Project. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet 2000;355:675-687. Go to original source... Go to PubMed...
  15. Cífková R, Bruthans J, Wohlfahrt P, et al. Major cardiovascular risk factors in the Czech population: 30-year trends between 1985 and 2016/17. Czech MONICA and Czech post-MONICA, odesláno do tisku.
  16. Organisation for Economic Co-operation and Development. Obesity update 2017. OECD https://www.oecd.org/els/health-systems/Obesity-Update-2017.pdf (2017).
  17. Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol 2019;15:288-298. Go to original source... Go to PubMed...
  18. Williamson DF, Madans J, Anda RF, et al. Smoking cessation and severity of weight gain in a national cohort. N Engl J Med 1991;324:739-745. Go to original source... Go to PubMed...
  19. Krauss RM, Winston M, Fletcher BJ, Grundy SM. Obesity : Impact on Cardiovascular Disease. Circulation 1998;98:1472-1476. Go to original source...
  20. Bray GA, Kim KK, Wilding JPH, World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev 2017;18:715-723. Go to original source... Go to PubMed...
  21. Eckel RH. Obesity and heart disease. A statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1997;96: 3248-3250. Go to original source... Go to PubMed...
  22. Dengel DR, Galeckim AT, Hagberg JM, Pratley RE. The independent and combined effects of weight loss and aerobic exercise on blood pressure and oral glucose tolerance in older men. Am J Hypertens 1998;11:1405-1412. Go to original source... Go to PubMed...
  23. GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet 2017;389:1885-1906. Go to original source... Go to PubMed...
  24. Benjamin EJ, Muntner P, Alonso A, et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation 2019;139:e56-e528. Go to original source... Go to PubMed...
  25. Cifkova R, Pitha J, Krajcoviechova A, Kralikova E. Is the impact of conventional risk factors the same in men and women? Plea for a more gender-specific approach. Int J Cardiol 2019;286:214-219. Go to original source... Go to PubMed...
  26. Howard G, Wagenknecht LE, Burke GL, et al. Cigarette smoking and progression of atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. JAMA 1998;279:119-124. Go to original source... Go to PubMed...
  27. Mills KT, Bundy JD, Kelly TN, et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016;134:441-450. Go to original source... Go to PubMed...
  28. Cífková R, Skodová Z, Bruthans J, et al. Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2007/2008. J Hypertens 2010;28:2196-2203. Go to original source... Go to PubMed...
  29. Elliott P, Stamler J, Nichols R, et al.; for the Intersalt Cooperative Research Group. Intersalt revisited: furtheranalyses of 24-hour sodium excretion and blood pressure within and across populations. BMJ 1996;312:1249-1253. Go to original source... Go to PubMed...
  30. Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? Analysis of data from trials of salt reduction. BMJ 1991;302:819-824. Go to original source... Go to PubMed...
  31. Cutler JA, Follmann D, Alender PS. Randomized trials of sodium reduction: an overview. Am J Clin Nutr 1997;65:643S-651S. Go to original source... Go to PubMed...
  32. Midgley JP, Matthev AG, Greenwood CMT, Logan AG. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA 1996;275:1590-1597. Go to original source... Go to PubMed...
  33. Sacks FM, Svetkey LP, Vollmer WM, et al.; for the DASH-sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Eng J Med 2001;344:3-10. Go to original source... Go to PubMed...
  34. Timmis A, Townsend N, Gale CP, et al. European Society of Cardiology: Cardiovascular Disease Statistics 2019. Eur Heart J 2020;41:12-85. Go to original source... Go to PubMed...
  35. Puddey IB, Beilin LJ, Rakic V. Alcohol, hypertension and the cardiovascular system: a critical appraisal. Addiction Biol 1997;2:159-170. Go to original source... Go to PubMed...
  36. Mills KT, Bundy JD, Kelly TN, et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation 2016;134:441-450. Go to original source... Go to PubMed...
  37. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300. Go to original source... Go to PubMed...
  38. Williams B, Mancia G, Spiering W, et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2018;36:2284-2309. Go to original source... Go to PubMed...
  39. Conn VS, Ruppar TM, Chase JA, et al. Interventions to improve medication adherence in hypertensive patients: systematic review and meta-analysis. Curr Hypertens Rep 2015;17:94. Go to original source... Go to PubMed...
  40. Vartiainen E, Puska P, Pekkanen J, et al. Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland. BMJ 1994;309:23-27. Go to original source... Go to PubMed...
  41. World Health Organization. Global report on diabetes. Geneva (Switzerland), World Health Org. 2016.
  42. Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentrations, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;26;375:2215-2222. Go to original source... Go to PubMed...
  43. The DECODE Study Group on behalf of the European Diabetes Epidemiology Group: Glucose tolerance and Cardiovascular Mortality. Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001:161;397-404. Go to original source... Go to PubMed...
  44. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197. Go to original source... Go to PubMed...
  45. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1. Diagnosis and Classification of Diabetes Mellitus. Geneva (Switzerland), World Health Org. 1999.
  46. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO consultation/IDF Consultation. Geneva (Switzerland), World Health Org. 2006.
  47. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. International Expert Committee. Diabetes Care 2009;32:1327-1334.
  48. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-524. Go to original source... Go to PubMed...
  49. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 2016;387:1513-1530.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.





Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.